2. Academic Validation
  3. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide

  • Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. doi: 10.1128/AAC.48.7.2693-2696.2004.
Chang-Jer Wu 1,  Jia-Tsrong Jan,  Chi-Min Chen,  Hsing-Pang Hsieh,  Der-Ren Hwang,  Hwan-Wun Liu,  Chiu-Yi Liu,  Hui-Wen Huang,  Su-Chin Chen,  Cheng-Fong Hong,  Ren-Kuo Lin,  Yu-Sheng Chao,  John T A Hsu
Affiliations

Affiliation

  • 1 Institute of Preventive Medicine, National Defense Medical College, National Defense University, Taipei, Taiwan.
PMID: 15215127 DOI: 10.1128/AAC.48.7.2693-2696.2004
Abstract

Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV Infection.

Figures
Products